Info

🌱 來自: mantle cell lymphoma

Relapsed Disease of mantle cell lymphoma

• No generally accepted standard of care; clinical trial enrollment encouraged The above described initial Rx regimens are typically also active in the relapsed setting if not already used
• Lenalidomide plus rituximab is active in relapsed MCL (Lancet Oncol 2012;13:716)
• Ibrutinib is active in relapsed MCL (NEJM 2013;369:507) & can consider addition of rituximab (Lancet Oncol 2015;17:48)
• Venetoclax is active in relapsed MCL (JCO 2016;70:4320)
• Bortezomib (± rituximab) has been approved for salvage Rx based on a single agent ORR of 33% w/ 8% CRs (JCO 2006;24:4867).
• Long-term disease control can be achieved w/ allogeneic SCT. Compared to autologous SCT, allo SCT is a/w increased tox, but improved disease control